Featured Research

from universities, journals, and other organizations

Breakthrough announced in treatment of patient with rare type of leukaemia

Date:
January 15, 2014
Source:
University of Leicester
Summary:
A team of scientists has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer.

L to R: Jesvin Samuel, Dr Salvador Macip and Professor Martin Dyer.
Credit: University of Leicester

A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer.

Related Articles


The research, which is published today in the New England Journal of Medicine, indicates Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, is also successful in treating Leukemia. The study shows the treatment, which can be taken orally, cleared the malignant cells from the patient's blood and led to a complete clinical recovery in a number of days.

The study was led by the University of Leicester and involved treatment of a patient at the Leicester Royal Infirmary.

Dr Salvador Macip, from the University of Leicester's Department of Biochemistry, explained: "A genetic study of the patient's blood cells allowed us to identify a mutation in the BRAF gene that is commonly found in skin cancers. This knowledge enabled us to combat the cancer cells with Vemurafenib, which has had proven success as a BRAF inhibitor in melanomas, and showed similar success for this patient who had exhausted all other treatment options, which is fantastic.

"What was most surprising was that the drug did not work in the way we expected it to. Whilst it successfully blocked BRAF and killed the cancerous cells, there was no ability to block the downstream cascade of signals. Therefore more research is required to better understand how this drug works to ensure we are able to use it in the best possible way.

"This is one of the first clinical examples of this treatment for HCL and we are the first researchers to do a biochemical study of the samples and discover that the drug does not do what it's supposed to be doing."

This approach to targeting cancer is an example of precision medicine with clinicians and research scientists working side-by-side to ensure the best treatment, tailored to the individual patient, was provided.

Professor of Haemato-Oncology at the University of Leicester, Professor Martin Dyer, who is Honorary Consultant Physician, Department of Haematology at Leicester's Hospitals, said: "Precision medicine in which clinicians and basic scientists collaborate to deliver novel and rapid personalised therapies to cancer patients like this is essential.

"We drew blood from the patient on a daily basis which was analysed back in the lab to monitor the effects of the drug. The more understanding we have of how treatments such as Vemurafenib kill cancer cells, the more effective and targeted treatments can be."

Professor Dyer is based in the University of Leicester's Department of Cancer Studies and Molecular Medicine and the treatment of the patient took place at the Leicester Royal Infirmary.

This research shows that drugs currently used to target certain cancers could be applied in other malignancies that share similar genetic backgrounds.

University of Leicester Pro-Vice-Chancellor and Head of the College of Medicine, Biological Sciences and Psychology, Professor David Wynford-Thomas, said: "The importance of the close working partnership between the University of Leicester and Leicester's Hospitals is highlighted in advances such as this. World-class research at the University brings direct benefits to patients in Leicester's hospitals in diverse areas including cardiovascular health, kidney research, lung health, diabetes, cancer research and many other areas.

"I am delighted that our research has had such a direct benefit locally -- it is another first for the University of Leicester and Leicester Royal Infirmary."


Story Source:

The above story is based on materials provided by University of Leicester. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jesvin Samuel, Salvador Macip, Martin J.S. Dyer. Efficacy of Vemurafenib in Hairy-Cell Leukemia. New England Journal of Medicine, 2014; 370 (3): 286 DOI: 10.1056/NEJMc1310849

Cite This Page:

University of Leicester. "Breakthrough announced in treatment of patient with rare type of leukaemia." ScienceDaily. ScienceDaily, 15 January 2014. <www.sciencedaily.com/releases/2014/01/140115172704.htm>.
University of Leicester. (2014, January 15). Breakthrough announced in treatment of patient with rare type of leukaemia. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2014/01/140115172704.htm
University of Leicester. "Breakthrough announced in treatment of patient with rare type of leukaemia." ScienceDaily. www.sciencedaily.com/releases/2014/01/140115172704.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com
Hugging It Out Could Help You Ward Off A Cold

Hugging It Out Could Help You Ward Off A Cold

Newsy (Dec. 21, 2014) Carnegie Mellon researchers found frequent hugs can help people avoid stress-related illnesses. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins